News Archives - Page 1450 of 1458

MondayOct 31, 2016 3:21 pm

Neovasc, Inc. (NVCN) Presenting at the Transcatheter Cardiovascular Therapeutics Symposium

As announced late last week, Neovasc, Inc. (NASDAQ: NVCN), a specialty medical device company, made multiple presentations today at the annual Transcatheter Cardiovascular Therapeutics (TCT) symposium in Washington, D.C., the world's largest educational meeting specializing in interventional cardiovascular medicine. Dr. Anson Cheung, professor of surgery and director of cardiac transplant at St. Paul’s Hospital in Vancouver, Canada, offered an update on the clinical development of the Tiara™ for the transcatheter treatment of mitral valve disease. Meanwhile, Dr. Gregg Stone highlighted the clinical results of the Neovasc Reducer™ for the treatment of refractory angina. This year’s TCT symposium kicked off on…

MondayOct 31, 2016 12:04 pm

Catalyst Pharmaceuticals, Inc. (CPRX): FDA OKs Phase 3 Firdapse Study; Shares Higher

Shares of Catalyst Pharmaceuticals (NASDAQ: CPRX) are 11% higher after the biopharmaceutical company announced its agreement with the U.S. Food and Drug Administration (FDA) under a Special Protocol Assessment (SPA) for the protocol design, clinical endpoints, and statistical analysis approach of the company’s upcoming phase 3 study evaluating Firdapse® for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS). Calling the SPA a “major milestone,” Catalyst CEO Patrick J. McEnany said the company now has a regulatory pathway for Firdapse. Catalyst expects to initiate this trial before the end of this year. To view the full press release, visit: http://nnw.fm/S3sgt About…

FridayOct 28, 2016 3:27 pm

Liquidmetal Technologies, Inc. (LQMT) Advances with EONTEC Collaboration following Completion of $63.4 Million Equity Raise

Earlier this week, Liquidmetal Technologies, Inc. (OTCQB: LQMT) announced completion of the additional closing pursuant to a securities purchase agreement signed with a Hong Kong company owned by Professor Lugee Li in March of this year. Notably, Professor Li is also the Chairman and majority shareholder of EONTEC, a global manufacturing company headquartered in Hong Kong with manufacturing plants in China. In conjunction with this investment, Professor Li became the Chairman of the Board. In a quote, he expressed his excitement to fully incorporate EONTEC’s capabilities with LQMT’s focus on production of high-performance parts, allowing LQMT to address a broad…

FridayOct 28, 2016 1:36 pm

Idera Pharmaceuticals, Inc. (IDRA) Widens Loss in Q3, Shares Lower

Idera Pharmaceuticals (NASDAQ: IDRA) posted a third-quarter net loss of $12.9 million, or $(0.10) per basic and diluted share, compared to a net loss of $11.4 million, or $(0.10) per basic and diluted share, for the same period in 2015. Revenue for the 2016 quarter totaled $0.3 million vs. nominal revenue a year ago. To view the full press release, visit: http://nnw.fm/3FPPy About Idera Pharmaceuticals, Inc. Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases. Idera’s proprietary technology involves using a TLR-targeting technology, to design synthetic oligonucleotide-based drug…

FridayOct 28, 2016 1:34 pm

Wider Q1 Loss, Lower Sales Drag ImmunoGen, Inc. (IMGN) Shares Lower

ImmunoGen (NASDAQ: IMGN) shares are lower after the company posted a quarterly net loss of $44.7 million, or $(0.51) per basic and diluted share, on revenues of $7.7 million vs. a net loss of $33.7 million, or $(0.39) per basic and diluted share, on revenues of $14.9 million the year prior. To view the full press release, visit: http://nnw.fm/Jgg6N About ImmunoGen, Inc. ImmunoGen is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its proprietary ADC technology. ImmunoGen's lead product candidate, mirvetuximab soravtansine, is being advanced to a Phase 3 trial for FRα-positive platinum-resistant ovarian cancer, and is in Phase 1b/2 testing…

FridayOct 28, 2016 1:33 pm

Opexa Therapeutics’ (OPXA) Tcelna Misses Endpoints in MS Study, Shares Plunge

Shares of Opexa Therapeutics (NASDAQ: OPXA) sank 68% in morning trade on news the biopharmaceutical company’s phase 2b Abili-T clinical trial to evaluate the efficacy and safety of Tcelna® (imilecleucel-T) in patients with secondary progressive multiple sclerosis (SPMS) failed to meet primary endpoint of reduction in brain volume change (atrophy), nor did it meet the secondary endpoint of reduction of the rate of sustained disease progression. The drug candidate did show a favorable safety and tolerability profile. To view the full press release, visit: http://nnw.fm/eHA99 About Opexa Therapeutics Opexa Therapeutics is a biopharmaceutical company developing personalized immunotherapies based on ImmPath®,…

ThursdayOct 27, 2016 1:57 pm

Inventory Increase Pushes EXOlifestyle, Inc. (EXOL) Shares Higher

Shares of EXOlifestyle (OTCQB: EXOL) climbed 9% in mid-day trade on news of the company’s inventory expansion. The developer of innovative and healthy brands within the health and wellness industry this morning announced that to meet rising demand of its products, it has ordered additional inventory with a retail value of $400,000. To view the full press release, visit: http://nnw.fm/X3yBD About EXOlifestyle Inc. EXOlifestyle Inc. is a management firm which develops and operates innovative and healthy brands within the health & wellness industry with a strong focus on athletic apparel. EXO is a functional sports apparel brand, and designer and producer of active wear products…

WednesdayOct 26, 2016 1:49 pm

Cemtrex, Inc. (CETX) Preliminary FY2016 Results Drive Shares Higher

Shares of Cemtrex (NASDAQ: CETX) are 10% higher in mid-day trade after the industrial and manufacturing solutions company announced preliminary financial results for the fiscal year ended September 30, 2016. Cemtrex said it expects revenues in the range of $93 million to $95 million compared to revenues of $56 million in fiscal 2015; net income in the range of $4.8 million to $5.0 million compared to net income of $2.8 million in fiscal 2015; and EBITDA in the range of $6.6 million to $7.0 million compared to $3.9 million a year ago. EPS is expected to increase to $0.52 per…

WednesdayOct 26, 2016 1:46 pm

Amyris (AMRS) Inks Collaboration Deal with Global Nutraceuticals Partner, Q3 Results Ahead

Amyris (NASDAQ: AMRS) this morning announced definitive agreements for its strategic partnership and financing with a global nutraceuticals market leader, as previously described in September. As a result of new markets and products stemming from the collaboration, the industrial bioscience company forecasts annual revenue of roughly $100 million at full-scale production expected in 2019. Amyris is scheduled to post its third-quarter results November 2, 2016. To view the full press release, visit: http://nnw.fm/1oIGZ About Amyris Amyris is the integrated renewable products company that is enabling the world’s leading brands to achieve sustainable growth. Amyris applies its innovative bioscience solutions to…

TuesdayOct 25, 2016 3:47 pm

Second Sight (EYES) Shares Soar on Implant and Activation of Wireless Visual Cortical Stimulator in First Human Subject

Shares of Second Sight Medical Products (NASDAQ: EYES) are moving higher on news that the implantable visual prosthetics company has successfully implanted and activated a wireless visual cortical stimulator in a human subject. The company said the achievement provides the initial human proof of concept for the ongoing development of the company’s Orion™ I Visual Cortical Prosthesis (Orion I). “Based on these results, stimulation of the visual cortex has the potential to restore useful vision to the blind, which is important for independence and improving quality of life,” Dr. Nader Pouratian, the UCLA neurosurgeon who performed the surgery, stated in…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

Breaks Categories: News